Showing results (91-100 of 203) with videos related to
Sort By:
Pageof 21
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 15, 2014
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis BAmoreena C Corsa, Yang Liu, John F Flaherty, et al.Journal of Medical Virology|May 28, 2014
Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDFYang Liu, Scott Fung, Edward J Gane, et al.Viruses|September 27, 2016
Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C SubstitutionsMing-Tain Lai, Vandna Munshi, Meiqing Lu, et al.Retrovirology|May 15, 2009
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action studyJoy Y Feng, John K Ly, Florence Myrick, et al.Antimicrobial Agents and Chemotherapy|February 26, 2004
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutationsKirsten L White, James M Chen, Nicolas A Margot, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 2, 2007
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosineEvguenia S Svarovskaia, Nicolas A Margot, Andrew S Bae, et al.Antiviral Therapy|May 28, 2005
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudineAdrian S Ray, Florence Myrick, Jennifer E Vela, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2011
The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitnessRima Kulkarni, Kerim Babaoglu, Eric B Lansdon, et al.The Journal of Infectious Diseases|March 5, 2005
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudineDiane V Havlir, Kersten K Koelsch, Matthew C Strain, et al.The Journal of Antimicrobial Chemotherapy|February 11, 2014
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adultsMartin Markowitz, Andrew Zolopa, Kathleen Squires, et al.Pageof 21